CVRx, Inc.
No enriched coverage for $CVRX in the last 7 days.
No SEC Form 4 filings for $CVRX in the last 30 days.
CVRx announced the 25th successful Barostim implant at UNC Medical Center in Chapel Hill, highlighting the collaborative efforts of the medical team. This milestone follows a 20% increase in CVRx's first-quarter revenue and the commencement of patient enrollment for its BENEFIT-HF clinical trial, underscoring the company's growth and contributions to cardiac care.
Medtronic has made an all-cash offer to acquire CVRx Inc for approximately $300 million, bringing the heart-device specialist into focus for investors. The acquisition highlights the strategic value of CVRx's Barostim device, which treats heart failure and hypertension, and Medtronic's aim to expand its cardiovascular portfolio. The deal provides CVRx with access to Medtronic's global infrastructure and offers liquidity to shareholders, reflecting how larger companies seek innovation from smaller, publicly traded firms.
CVRx shares recovered after Humana announced a Medicare Advantage coverage policy for CVRx's Barostim cardiac implant. This news follows a post-earnings decline for the MedTech firm.
